Generic drug: doravirine

Brand name: Pifeltro

What is Pifeltro (doravirine), and how does it work?

Pifeltro (doravirine) is a prescription medicine that is used together with other HIV-1 medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults:

  • who have not received HIV-1 medicines in the past, or
  • to replace their current HIV-1 medicines for people whose healthcare provider determines that they meet certain requirements.

HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

It is not known if Pifeltro is safe and effective in children under 18 years of age.

What are the side effects of Pifeltro?

Pifeltro can cause serious side effects, including:

  • Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your doctor right away if you start having any new symptoms after starting your HIV-1 medicine.

The most common side effects of Pifeltro include:

These are not all the possible side effects of Pifeltro.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is the dosage for Pifeltro?

Recommended Dosage

  • The recommended dosage regimen of Pifeltro in adults is one 100 mg tablet taken orally once daily with or without food.

Dosage Adjustment With Rifabutin

  • If Pifeltro is co-administered with rifabutin, increase Pifeltro dosage to one tablet twice daily (approximately 12 hours apart) for the duration of rifabutin co-administration.

What drugs interact with Pifeltro?

Effect Of Other Drugs On Pifeltro

Co-administration of Pifeltro with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce Pifeltro efficacy. Co-administration of Pifeltro and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine.

Table 6 shows significant drug interactions with Pifeltro.

Table 6: Drug Interactions with Pifeltro*

Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment
Androgen Receptors
enzalutamide ↓doravirine Co-administration is contraindicated with enzalutamide.
At least a 4-week cessation period is recommended prior to initiation of Pifeltro.
Anticonvulsants
carbamazepine
oxcarbazepine
phenobarbital
phenytoin
↓ doravirine Co-administration is contraindicated with these anticonvulsants. At least a 4-week cessation period is recommended prior to initiation of Pifeltro.
Antimycobacterials
rifampin†
rifapentine
↓ doravirine Co-administration is contraindicated with rifampin or rifapentine. At least a 4-week cessation period is recommended prior to initiation of Pifeltro.
rifabutin† ↓ doravirine Increase Pifeltro dosage to one tablet twice daily when co-administered with rifabutin.
Cytotoxic Agents
mitotane ↓ doravirine Co-administration is contraindicated with mitotane. At least a 4-week cessation period is recommended prior to initiation of Pifeltro.
HIV Antiviral Agents
efavirenz†
etravirine
nevirapine
↓ doravirine Use with efavirenz, etravirine, or nevirapine is not recommended.
Herbal Products
St. John’s wort ↓doravirine Co-administration is contraindicated with St. John’s wort. At least a 4-week cessation period is recommended prior to initiation of Pifeltro.
↑ = increase, ↓ = decrease
*This table is not all inclusive.
†The interaction between Pifeltro and the concomitant drug was evaluated in a clinical study.
All other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways.

No clinically significant changes in concentration were observed for doravirine when co-administered with the following agents:

Effect Of Pifeltro On Other Drugs

No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine:

SLIDESHOW

A Timeline of the HIV/AIDS Pandemic See Slideshow

Is Pifeltro safe to use while pregnant or breastfeeding?

  • No adequate human data are available to establish whether or not Pifeltro poses a risk to pregnancy outcomes.
  • There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to Pifeltro during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.
  • The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers in the United States not breastfeed their infants to avoid risking potential transmission of HIV-1 infection.
  • It is unknown whether doravirine is present in human milk, affects human milk production, or has effects on the breastfed infant.
  • Because of the potential for (1) HIV-1 transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants), and (3) serious adverse reactions in a breastfed infant, mothers should not breastfeed if they are receiving Pifeltro.

Summary

Pifeltro (doravirine) is a prescription medicine that is used together with other HIV-1 medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults. Serious side effects of Pifeltro include changes in your immune system (Immune Reconstitution Syndrome).

Treatment & Diagnosis

Medications & Supplements

Prevention & Wellness

QUESTION

What is HIV? See Answer

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 6/16/2021
References
All sections courtesy of the U.S. Food and Drug Administration